Drug intelligence / Profile preview

SF2506

Development stage: Preclinical
Lead developer: Semafore Pharmaceuticals
Modality: Small Molecules

Overview

SF2506 is a small molecule, multi-targeted kinase inhibitor developed by Semafore Pharmaceuticals for the treatment of cancer. It is designed to inhibit multiple kinases within the PI3K/PTEN signaling pathway, specifically targeting all Class I isoforms of phosphoinositide 3-kinase (PI3K), the mammalian target of rapamycin (mTOR), DNA-dependent protein kinase (DNA-PK), and PIM-1 kinase. Developed using a proprietary kinase scaffold and computational modeling, SF2506 has demonstrated significantly greater potency compared to the PI3K inhibitor LY294002 and has shown the ability to induce apoptosis in renal cell carcinoma cell lines.

Targets

DNA-PK (DNA-dependent protein kinase)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)PIM1 (Proviral integration site for moloney murine leukemia virus kinase 1)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on SF2506.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SF2506.